Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

2.62
-0.0500-1.87%
Post-market: 2.630.0097+0.37%19:49 EST
Volume:765.91K
Turnover:2.02M
Market Cap:283.86M
PE:-2.00
High:2.69
Open:2.69
Low:2.61
Close:2.67
52wk High:3.48
52wk Low:1.05
Shares:108.35M
Float Shares:72.65M
Volume Ratio:1.19
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3077
EPS(LYR):-1.7085
ROE:-113.23%
ROA:-22.98%
PB:2.36
PE(LYR):-1.53

Loading ...

Aclaris Therapeutics Launches Phase 1b Trial of Bispecific Antibody ATI-052 in Atopic Dermatitis

Reuters
·
Jan 12

Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Atopic Dermatitis (Ad) With Its Novel Bispecific Antibody ATI-052

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - Top Line Results From Poc Trials Expected in H2 2026

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - to Initiate Phase 1B Trial in Asthma This Quarter

THOMSON REUTERS
·
Jan 12

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla

Reuters
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile

MT Newswires Live
·
Jan 06

BUZZ-Aclaris rises as inflammation drug shows promise in early trial

Reuters
·
Jan 06

Aclaris Therapeutics Inc: Expects Top Line Data From Both Trials in Second Half of 2026.

THOMSON REUTERS
·
Jan 06

Aclaris Therapeutics Inc - to Initiate Phase 1B Poc Trials in Ad and Asthma in 2026

THOMSON REUTERS
·
Jan 06

Aclaris Therapeutics Inc - Phase 2B Trial of ATI-052 in Ad Expected to Initiate in H2 2026

THOMSON REUTERS
·
Jan 06

Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile up to 720 Mg

THOMSON REUTERS
·
Jan 06

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

GlobeNewswire
·
Jan 06

Aclaris Therapeutics Included in Nasdaq Biotechnology Index

MT Newswires Live
·
Dec 20, 2025

Aclaris Therapeutics Joins Nasdaq Biotechnology Index

Reuters
·
Dec 20, 2025

Aclaris Therapeutics management to meet with Cantor

TIPRANKS
·
Nov 28, 2025

Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million

Reuters
·
Nov 20, 2025

Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate

Benzinga
·
Nov 06, 2025

Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows

Reuters
·
Nov 06, 2025